SPDR S&P Biotech ETF
195 hedge funds and large institutions have $2.3B invested in SPDR S&P Biotech ETF in 2016 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 63 increasing their positions, 60 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
17.66% less ownership
Funds ownership: 136.68% → 119.02% (-18%)
27% less capital invested
Capital invested by funds: $3.15B → $2.3B (-$858M)
30% less call options, than puts
Call options by funds: $641M | Put options by funds: $913M
Holders
195
Holding in Top 10
5
Calls
$641M
Puts
$913M
Top Buyers
| 1 | +$120M | |
| 2 | +$110M | |
| 3 | +$50.7M | |
| 4 |
Millennium Management
New York
|
+$20.6M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
+$17.2M |
Top Sellers
| 1 | -$306M | |
| 2 | -$51.2M | |
| 3 | -$42M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$32.7M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$20.8M |